^
Association details:
| Biomarker: | EGFR-SEPTIN14 fusion + EGFR amplification |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Rare EGFR-SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib
Excerpt:
Here we describe a case of a 63-year-old man...Paraffin sections of postoperative colorectal tissue were subjected to next-generation sequencing, and epidermal growth factor receptor (EGFR) amplification and rare EGFR-SEPT14 fusion were identified. The patient then received erlotinib, an EGFR tyrosine kinase inhibitor (TKI), and achieved a partial response.
DOI:
10.1634/theoncologist.2019-0405
